All News

Found 239 articles

• Checkmate Pharmaceuticals Announces CEO TransitionAlan Fuhrman, experienced biotech executive and Checkmate board member, appointed as interim President and CEO

  10/27/2021

  Checkmate Pharmaceuticals, Inc. today announced that Alan Fuhrman has been appointed as interim President and CEO.

• SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors

  10/20/2021

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into an exclusive worldwide license agreement with Dana-Farber Cancer Institute (Dana-Farber) and a sponsored research agreement (SRA) with Stanford Medicine for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor (EGFR) designed for the treatment of EGFR-mutant lung cancers.

• SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

  10/20/2021

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into a collaboration agreement with Ab Magnitude Ventures Group, LLC and Ab Magnitude Fund, LP (collectively, “Ab Magnitude”) for the development of next-generation targeted oncology therapeutics.

• SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference.

• 

  SpringWorks Teams with Dana-Farber Institute on Potential Cancer Therapy

  8/30/2021

  ​SpringWorks has announced a research collaboration with the Dana-Farber Cancer Institute to advance its therapy development efforts for multiple myeloma and related diseases.

• SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

  8/30/2021

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that it has entered into a sponsored research collaboration with Dana-Farber Cancer Institute.

• Neurofibromatosis Type I Market to Record Significant Revenue Growth During the Forecast Period 2021-2028

  8/27/2021

  A recent market research report added to repository of Credible Markets is an in-depth analysis of Neurofibromatosis Type I Market.

• Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/12/2021

  Precision BioSciences, Inc. today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

• Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

  8/12/2021

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to ALLO-715 for the treatment of multiple myeloma.

• 

  Clinical Catch-Up: August 2-6

  8/9/2021

  It was a busy week for clinical trial announcements. Take a look.

• Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

  8/5/2021

  Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for genetic diseases, today announced results for the three-month and first six-month periods ending June 30, 2021.

• SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

  8/4/2021

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported financial results for the second quarter and year-to-date periods ended June 30, 2021 and provided an update on recent company developments.

• Allogene Therapeutics Reports Second Quarter 2021 Financial Results

  8/4/2021

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported second quarter 2021 financial results for the quarter ended June 30, 2021.

• SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

  8/3/2021

  SpringWorks Therapeutics, Inc. announced that the Company will be evaluating mirdametinib, an investigational MEK inhibitor, in a platform study sponsored by Memorial Sloan Kettering Cancer Center and supported by SpringWorks exploring the compound both as a monotherapy and as a combination therapy in advanced solid tumors harboring MAPK-activating mutations.

• SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

  8/3/2021

  SpringWorks Therapeutics, Inc. today announced that management will participate in a Fireside Chat at the 12th Annual Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 9:45AM ET.

• 

  BioSpace Movers & Shakers, July 30, 2021

  7/30/2021

  Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.

• SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer

  7/27/2021

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that James (Jim) Cassidy, M.D., Ph.D., has been appointed Chief Medical Officer.

• SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041

  7/20/2021

  SpringWorks Therapeutics, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,066,358 (the ‘358 patent), directed to mirdametinib, the Company’s product candidate in development for several oncology indications, including as a monotherapy for patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

• 

  Clinical Catch-Up: June 28-July 2

  7/6/2021

  It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.

• Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

  6/30/2021

  Allogene Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma.